Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 05 August, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 524558 | NSE: NEULANDLAB

Neuland Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 4, 2025, 11:10 am

Market Cap 16,295 Cr.
Current Price 12,701
High / Low 18,100/10,060
Stock P/E124
Book Value 1,188
Dividend Yield0.09 %
ROCE18.7 %
ROE14.8 %
Face Value 10.0
PEG Ratio4.70

Quick Insight

Neuland Laboratories Ltd, with a share price of ₹13,840 and a market capitalization of ₹17,759 Cr., appears to be trading at a high P/E ratio of 85.3. Despite this, the company boasts a respectable ROE of 14.8% and ROCE of 18.7%, indicating efficient capital utilization. With a net profit of ₹260 Cr. and healthy reserves of ₹1,512 Cr., Neuland seems well-positioned for growth. The company's comfortable Interest Coverage Ratio of 33.94x suggests a strong ability to service its borrowings of ₹157 Cr. However, investors may need to watch the high Price-to-Book Value of 6.32x. Overall, Neuland Laboratories presents a mixed picture for investors, combining solid financial performance with certain valuation challenges that merit further scrutiny.

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Neuland Laboratories Ltd

Competitors of Neuland Laboratories Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
Lactose (India) Ltd 140 Cr. 99.1 247/84.327.1 41.70.00 %12.9 %9.75 % 10.0
MPS Pharmaa Ltd 4.72 Cr. 2.47 4.33/2.47 0.570.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 36.6 Cr. 49.4 94.9/45.2 8.730.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 31.7 Cr. 21.6 29.1/13.131.1 6.830.00 %13.5 %11.0 % 10.0
Industry Average19,015.82 Cr1,190.8153.48193.550.32%16.63%15.27%6.18

All Competitor Stocks of Neuland Laboratories Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Sales 221294269407363418393385440311398328293
Expenses 193224215287266280272278316249311277258
Operating Profit 2969541209713712110712362875134
OPM % 13%24%20%29%27%33%31%28%28%20%22%16%12%
Other Income 101823252546078
Interest 3334244431225
Depreciation 13131313141515161616161720
Profit before tax 1353391108312210492130491283918
Tax % 26%28%22%23%26%27%22%27%25%34%20%29%21%
Net Profit 103831856289816898331022814
EPS in Rs 7.7729.9823.8165.8948.2369.5663.4452.6676.2825.6079.1821.6810.83

Last Updated: August 1, 2025, 4:25 pm

Below is a detailed analysis of the quarterly data for Neuland Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

  • For Sales, as of Jun 2025, the value is 293.00 Cr.. The value appears to be declining and may need further review. It has decreased from 328.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 35.00 Cr..
  • For Expenses, as of Jun 2025, the value is 258.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 277.00 Cr. (Mar 2025) to 258.00 Cr., marking a decrease of 19.00 Cr..
  • For Operating Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2025) to 34.00 Cr., marking a decrease of 17.00 Cr..
  • For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 12.00%, marking a decrease of 4.00%.
  • For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
  • For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
  • For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 3.00 Cr..
  • For Profit before tax, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 21.00 Cr..
  • For Tax %, as of Jun 2025, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 21.00%, marking a decrease of 8.00%.
  • For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 14.00 Cr..
  • For EPS in Rs, as of Jun 2025, the value is 10.83. The value appears to be declining and may need further review. It has decreased from 21.68 (Mar 2025) to 10.83, marking a decrease of 10.85.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:18 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales 4664695105795276677639379511,1911,5591,477
Expenses 3954024304724776086617908079181,0961,146
Operating Profit 7167801065158102147144273463331
OPM % 15%14%16%18%10%9%13%16%15%23%30%22%
Other Income 302143416091290
Interest 25272421191622181413148
Depreciation 151516192226314049536066
Profit before tax 3525426714205310582216401346
Tax % 23%36%36%30%13%19%69%23%22%24%25%25%
Net Profit 271627471216168164164300260
EPS in Rs 30.1217.9630.7552.7413.5712.8112.6362.8549.74127.45233.89202.74
Dividend Payout % 9%8%7%0%0%0%16%8%10%8%6%6%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-40.74%68.75%74.07%-74.47%33.33%0.00%406.25%-20.99%156.25%82.93%-13.33%
Change in YoY Net Profit Growth (%)0.00%109.49%5.32%-148.54%107.80%-33.33%406.25%-427.24%177.24%-73.32%-96.26%

Neuland Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:12%
5 Years:14%
3 Years:16%
TTM:-19%
Compounded Profit Growth
10 Years:29%
5 Years:67%
3 Years:47%
TTM:-59%
Stock Price CAGR
10 Years:38%
5 Years:76%
3 Years:129%
1 Year:19%
Return on Equity
10 Years:12%
5 Years:16%
3 Years:19%
Last Year:15%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:41 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 8999913131313131313
Reserves 1161521785375496866977748289811,2701,512
Borrowings 19018818219231923126418224112895157
Other Liabilities 169162155148194200257356302457454498
Total Liabilities 4835125248861,0711,1301,2311,3251,3831,5801,8332,180
Fixed Assets 131123139466475542653716767758824955
CWIP 35414020126104241720414648
Investments 77788887411109
Other Assets 3113403373934634765475855927819621,068
Total Assets 4835125248861,0711,1301,2311,3251,3831,5801,8332,180

Below is a detailed analysis of the balance sheet data for Neuland Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
  • For Reserves, as of Mar 2025, the value is 1,512.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,270.00 Cr. (Mar 2024) to 1,512.00 Cr., marking an increase of 242.00 Cr..
  • For Borrowings, as of Mar 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 95.00 Cr. (Mar 2024) to 157.00 Cr., marking an increase of 62.00 Cr..
  • For Other Liabilities, as of Mar 2025, the value is 498.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 454.00 Cr. (Mar 2024) to 498.00 Cr., marking an increase of 44.00 Cr..
  • For Total Liabilities, as of Mar 2025, the value is 2,180.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,833.00 Cr. (Mar 2024) to 2,180.00 Cr., marking an increase of 347.00 Cr..
  • For Fixed Assets, as of Mar 2025, the value is 955.00 Cr.. The value appears strong and on an upward trend. It has increased from 824.00 Cr. (Mar 2024) to 955.00 Cr., marking an increase of 131.00 Cr..
  • For CWIP, as of Mar 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2024) to 48.00 Cr., marking an increase of 2.00 Cr..
  • For Investments, as of Mar 2025, the value is 109.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 109.00 Cr., marking an increase of 108.00 Cr..
  • For Other Assets, as of Mar 2025, the value is 1,068.00 Cr.. The value appears strong and on an upward trend. It has increased from 962.00 Cr. (Mar 2024) to 1,068.00 Cr., marking an increase of 106.00 Cr..
  • For Total Assets, as of Mar 2025, the value is 2,180.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,833.00 Cr. (Mar 2024) to 2,180.00 Cr., marking an increase of 347.00 Cr..

Notably, the Reserves (1,512.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +4913453911705718960237261317
Cash from Investing Activity +-10-14-20-42-116-77-49-84-95-61-150-298
Cash from Financing Activity +-391-24-010512-5-11438-136-6925
Net Cash Flow-001-4-053-93404244

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-119.00-121.00-102.00-86.00-268.00-173.00-162.00-35.00-97.00145.00368.00174.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

No data available for the Financial Efficiency data table.

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters36.22%36.22%36.22%36.14%36.14%36.03%35.97%32.80%32.74%32.72%32.64%32.68%
FIIs17.21%17.39%17.68%17.70%18.14%20.19%21.57%22.69%24.43%25.72%26.46%23.86%
DIIs6.38%6.45%6.57%6.54%7.10%6.76%6.99%6.02%6.54%6.39%6.38%9.09%
Government0.00%0.00%0.44%0.46%0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.40%
Public40.19%39.94%39.07%39.15%38.22%36.62%35.08%38.10%35.88%34.77%34.12%33.96%
No. of Shareholders32,25731,97630,60029,66926,94825,22326,82427,72328,61629,07734,56739,315

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 116,449 0.57 63.66116,4492025-04-22 17:25:250%
WhiteOak Capital Flexi Cap Fund 57,756 1.19 31.5757,7562025-04-22 17:25:250%
WhiteOak Capital Mid Cap Fund 27,505 1.15 15.0427,5052025-04-22 17:25:250%
WhiteOak Capital Multi Cap Fund 11,091 1.17 6.0611,0912025-04-22 17:25:250%
Motilal Oswal Nifty Microcap 250 Index Fund 9,088 0.87 4.979,0882025-04-22 17:25:250%
WhiteOak Capital Balanced Advantage Fund 7,532 0.56 4.127,5322025-04-22 17:25:250%
WhiteOak Capital ELSS Tax Saver Fund 2,483 1.23 1.362,4832025-04-22 17:25:250%
WhiteOak Capital Large Cap Fund 2,111 0.31 1.152,1112025-04-22 17:25:250%
WhiteOak Capital Multi Asset Allocation Fund 1,882 0.42 1.031,8822025-04-22 17:25:250%
WhiteOak Capital Balanced Hybrid Fund 762 0.55 0.427622025-04-22 17:25:250%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 233.89127.4549.7462.8512.63
Diluted EPS (Rs.) 233.89127.4549.7462.8512.63
Cash EPS (Rs.) 278.89167.6687.4993.2636.81
Book Value[Excl.RevalReserv]/Share (Rs.) 993.65769.94650.88608.98549.68
Book Value[Incl.RevalReserv]/Share (Rs.) 994.31770.59651.52609.63550.33
Revenue From Operations / Share (Rs.) 1208.16923.37737.24726.26591.23
PBDIT / Share (Rs.) 368.31218.28112.16126.2981.99
PBIT / Share (Rs.) 322.03177.3774.1595.5257.75
PBT / Share (Rs.) 311.18167.2463.6981.6541.02
Net Profit / Share (Rs.) 232.61126.7549.4762.5012.57
NP After MI And SOA / Share (Rs.) 232.61126.7549.4762.5012.57
PBDIT Margin (%) 30.4823.6315.2117.3813.86
PBIT Margin (%) 26.6519.2010.0513.159.76
PBT Margin (%) 25.7518.118.6311.246.93
Net Profit Margin (%) 19.2513.726.718.602.12
NP After MI And SOA Margin (%) 19.2513.726.718.602.12
Return on Networth / Equity (%) 23.4016.467.6010.262.28
Return on Capital Employeed (%) 29.5720.059.3712.888.52
Return On Assets (%) 16.3710.354.616.081.31
Long Term Debt / Equity (X) 0.030.070.120.110.10
Total Debt / Equity (X) 0.060.120.270.180.34
Asset Turnover Ratio (%) 0.910.800.700.730.64
Current Ratio (X) 2.151.731.601.491.44
Quick Ratio (X) 1.331.100.870.810.82
Inventory Turnover Ratio (X) 2.011.791.711.881.90
Dividend Payout Ratio (NP) (%) 4.273.926.033.1830.53
Dividend Payout Ratio (CP) (%) 3.562.963.412.1310.42
Earning Retention Ratio (%) 95.7396.0893.9796.8269.47
Cash Earning Retention Ratio (%) 96.4497.0496.5997.8789.58
Interest Coverage Ratio (X) 33.9421.5510.729.104.90
Interest Coverage Ratio (Post Tax) (X) 22.4413.515.735.501.75
Enterprise Value (Cr.) 8068.902383.791534.952819.28564.23
EV / Net Operating Revenue (X) 5.182.001.613.010.73
EV / EBITDA (X) 16.988.4710.6117.315.33
MarketCap / Net Operating Revenue (X) 5.201.951.392.870.47
Retention Ratios (%) 95.7296.0793.9696.8169.46
Price / BV (X) 6.322.341.583.430.51
Price / Net Operating Revenue (X) 5.201.951.392.870.47
EarningsYield 0.030.070.040.020.04

After reviewing the key financial ratios for Neuland Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 233.89. This value is within the healthy range. It has increased from 127.45 (Mar 23) to 233.89, marking an increase of 106.44.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 233.89. This value is within the healthy range. It has increased from 127.45 (Mar 23) to 233.89, marking an increase of 106.44.
  • For Cash EPS (Rs.), as of Mar 24, the value is 278.89. This value is within the healthy range. It has increased from 167.66 (Mar 23) to 278.89, marking an increase of 111.23.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 993.65. It has increased from 769.94 (Mar 23) to 993.65, marking an increase of 223.71.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 994.31. It has increased from 770.59 (Mar 23) to 994.31, marking an increase of 223.72.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 1,208.16. It has increased from 923.37 (Mar 23) to 1,208.16, marking an increase of 284.79.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 368.31. This value is within the healthy range. It has increased from 218.28 (Mar 23) to 368.31, marking an increase of 150.03.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 322.03. This value is within the healthy range. It has increased from 177.37 (Mar 23) to 322.03, marking an increase of 144.66.
  • For PBT / Share (Rs.), as of Mar 24, the value is 311.18. This value is within the healthy range. It has increased from 167.24 (Mar 23) to 311.18, marking an increase of 143.94.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 232.61. This value is within the healthy range. It has increased from 126.75 (Mar 23) to 232.61, marking an increase of 105.86.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 232.61. This value is within the healthy range. It has increased from 126.75 (Mar 23) to 232.61, marking an increase of 105.86.
  • For PBDIT Margin (%), as of Mar 24, the value is 30.48. This value is within the healthy range. It has increased from 23.63 (Mar 23) to 30.48, marking an increase of 6.85.
  • For PBIT Margin (%), as of Mar 24, the value is 26.65. This value exceeds the healthy maximum of 20. It has increased from 19.20 (Mar 23) to 26.65, marking an increase of 7.45.
  • For PBT Margin (%), as of Mar 24, the value is 25.75. This value is within the healthy range. It has increased from 18.11 (Mar 23) to 25.75, marking an increase of 7.64.
  • For Net Profit Margin (%), as of Mar 24, the value is 19.25. This value exceeds the healthy maximum of 10. It has increased from 13.72 (Mar 23) to 19.25, marking an increase of 5.53.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 19.25. This value is within the healthy range. It has increased from 13.72 (Mar 23) to 19.25, marking an increase of 5.53.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 23.40. This value is within the healthy range. It has increased from 16.46 (Mar 23) to 23.40, marking an increase of 6.94.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 29.57. This value is within the healthy range. It has increased from 20.05 (Mar 23) to 29.57, marking an increase of 9.52.
  • For Return On Assets (%), as of Mar 24, the value is 16.37. This value is within the healthy range. It has increased from 10.35 (Mar 23) to 16.37, marking an increase of 6.02.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 23) to 0.03, marking a decrease of 0.04.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has decreased from 0.12 (Mar 23) to 0.06, marking a decrease of 0.06.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.91. It has increased from 0.80 (Mar 23) to 0.91, marking an increase of 0.11.
  • For Current Ratio (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has increased from 1.73 (Mar 23) to 2.15, marking an increase of 0.42.
  • For Quick Ratio (X), as of Mar 24, the value is 1.33. This value is within the healthy range. It has increased from 1.10 (Mar 23) to 1.33, marking an increase of 0.23.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.01. This value is below the healthy minimum of 4. It has increased from 1.79 (Mar 23) to 2.01, marking an increase of 0.22.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 4.27. This value is below the healthy minimum of 20. It has increased from 3.92 (Mar 23) to 4.27, marking an increase of 0.35.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 3.56. This value is below the healthy minimum of 20. It has increased from 2.96 (Mar 23) to 3.56, marking an increase of 0.60.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 95.73. This value exceeds the healthy maximum of 70. It has decreased from 96.08 (Mar 23) to 95.73, marking a decrease of 0.35.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 96.44. This value exceeds the healthy maximum of 70. It has decreased from 97.04 (Mar 23) to 96.44, marking a decrease of 0.60.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 33.94. This value is within the healthy range. It has increased from 21.55 (Mar 23) to 33.94, marking an increase of 12.39.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 22.44. This value is within the healthy range. It has increased from 13.51 (Mar 23) to 22.44, marking an increase of 8.93.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 8,068.90. It has increased from 2,383.79 (Mar 23) to 8,068.90, marking an increase of 5,685.11.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.18. This value exceeds the healthy maximum of 3. It has increased from 2.00 (Mar 23) to 5.18, marking an increase of 3.18.
  • For EV / EBITDA (X), as of Mar 24, the value is 16.98. This value exceeds the healthy maximum of 15. It has increased from 8.47 (Mar 23) to 16.98, marking an increase of 8.51.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.20. This value exceeds the healthy maximum of 3. It has increased from 1.95 (Mar 23) to 5.20, marking an increase of 3.25.
  • For Retention Ratios (%), as of Mar 24, the value is 95.72. This value exceeds the healthy maximum of 70. It has decreased from 96.07 (Mar 23) to 95.72, marking a decrease of 0.35.
  • For Price / BV (X), as of Mar 24, the value is 6.32. This value exceeds the healthy maximum of 3. It has increased from 2.34 (Mar 23) to 6.32, marking an increase of 3.98.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.20. This value exceeds the healthy maximum of 3. It has increased from 1.95 (Mar 23) to 5.20, marking an increase of 3.25.
  • For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 23) to 0.03, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Neuland Laboratories Ltd as of August 5, 2025 is: 17,457.44

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of August 5, 2025, Neuland Laboratories Ltd is Undervalued by 37.45% compared to the current share price 12,701.00

Intrinsic Value of Neuland Laboratories Ltd as of August 5, 2025 is: 22,065.18

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of August 5, 2025, Neuland Laboratories Ltd is Undervalued by 73.73% compared to the current share price 12,701.00

Last 5 Year EPS CAGR: 26.39%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neuland Laboratories Ltd:
    1. Net Profit Margin: 19.25%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 29.57% (Industry Average ROCE: 16.63%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 23.4% (Industry Average ROE: 15.27%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 22.44
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.33
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 124 (Industry average Stock P/E: 53.48)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.06
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Neuland Laboratories Ltd. is a Public Limited Listed company incorporated on 07/01/1984 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L85195TG1984PLC004393 and registration number is 004393. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 1476.84 Cr. and Equity Capital is Rs. 12.90 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals11th Floor (5th Office Level), Phoenix IVY Building, Hyderabad Telangana 500033ir@neulandlabs.com
http://www.neulandlabs.com
Management
NamePosition Held
Dr. Davuluri Rama Mohan RaoExecutive Chairman
Mr. Davuluri Sucheth RaoVice Chairman & CEO
Mr. Davuluri Saharsh RaoVice Chairman & Mng.Director
Dr. Christopher M CimarustiNon Executive Director
Mr. Homi Rustum KhusrokhanInd. Non-Executive Director
Mr. Prasad Raghava MenonInd. Non-Executive Director
Mr. Sugata SircarInd. Non-Executive Director
Ms. Pallavi Joshi BakhruInd. Non-Executive Director

FAQ

What is the intrinsic value of Neuland Laboratories Ltd?

Neuland Laboratories Ltd's intrinsic value (as of 04 August 2025) is ₹17457.44 which is 37.45% higher the current market price of ₹12,701.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 16,295 Cr. market cap, FY2025-2026 high/low of 18,100/10,060, reserves of 1,512 Cr, and liabilities of 2,180 Cr.

What is the Market Cap of Neuland Laboratories Ltd?

The Market Cap of Neuland Laboratories Ltd is 16,295 Cr..

What is the current Stock Price of Neuland Laboratories Ltd as on 04 August 2025?

The current stock price of Neuland Laboratories Ltd as on 04 August 2025 is 12,701.

What is the High / Low of Neuland Laboratories Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Neuland Laboratories Ltd stocks is ₹18,100/10,060.

What is the Stock P/E of Neuland Laboratories Ltd?

The Stock P/E of Neuland Laboratories Ltd is 124.

What is the Book Value of Neuland Laboratories Ltd?

The Book Value of Neuland Laboratories Ltd is 1,188.

What is the Dividend Yield of Neuland Laboratories Ltd?

The Dividend Yield of Neuland Laboratories Ltd is 0.09 %.

What is the ROCE of Neuland Laboratories Ltd?

The ROCE of Neuland Laboratories Ltd is 18.7 %.

What is the ROE of Neuland Laboratories Ltd?

The ROE of Neuland Laboratories Ltd is 14.8 %.

What is the Face Value of Neuland Laboratories Ltd?

The Face Value of Neuland Laboratories Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Neuland Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE